Pliant Capital Surpluse from 2010 to 2025

PLRX Stock  USD 10.66  0.08  0.74%   
Pliant Therapeutics Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 538.6 M in 2025. During the period from 2010 to 2025, Pliant Therapeutics Capital Surpluse regression line of annual values had r-squared of  0.49 and arithmetic mean of  463,890,405. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
751.8 M
Current Value
538.6 M
Quarterly Volatility
117.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.5 M, Net Interest Income of 23.2 M or Interest Income of 24.7 M, as well as many indicators such as Price To Sales Ratio of 636, Dividend Yield of 0.0 or PTB Ratio of 2.12. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pliant Therapeutics Correlation against competitors.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Latest Pliant Therapeutics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Pliant Therapeutics over the last few years. It is Pliant Therapeutics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Pliant Capital Surpluse Regression Statistics

Arithmetic Mean463,890,405
Geometric Mean452,448,656
Coefficient Of Variation25.30
Mean Deviation92,779,858
Median400,918,000
Standard Deviation117,357,453
Sample Variance13772.8T
Range350.8M
R-Value0.70
Mean Square Error7472.8T
R-Squared0.49
Significance0
Slope17,318,172
Total Sum of Squares206591.6T

Pliant Capital Surpluse History

2025538.6 M
2024751.8 M
2022653.7 M
2021414.3 M

About Pliant Therapeutics Financial Statements

Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse751.8 M538.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.